May 4, 2026
GSHTC administers first commercial hemophilia B gene therapy in Texas
The Gulf States Hemophilia and Thrombophilia Center (GSHTC) has successfully administered Hemgenix, the first FDA-approved gene therapy for Hemophilia B, to its first patients outside of a clinical trial setting — marking the first known commercial infusions of the therapy…